CSF3 and bone metastasis: Their results in the peripheral blood mononuclear cells of 131 progressive cancer patients, 37 healthy volunteers, and 5 patients who received granulocyte colony-stimulating factor showed that patients with metastatic disease had a significant increase in CD133 mRNA (P = 0.03), specifically patients with bone metastasis (P < 0.001).